N-Acetyl Semax Amidate and N-Acetyl Selank: A Research Review of Terminal-Capping Modifications, Enzymatic Resistance, BDNF/GABA Divergent Pathways and the Catalogue Vocabulary Behind "semax peptide bodybuilding", "na semax" and "na selank" Labels

By the Peptide Insider Research Desk · 42 catalogue-vocabulary strings indexed · 12 verified citations

The search strings na semax, na selank, semax/selank peptide and n acetyl semax amidate peptide populate research-reagent catalogues alongside orthographic neighbours such as semak peptide and the fill-mass descriptor semax 10mg. Each label encodes a terminal-capping modification strategy — N-acetylation, C-amidation, or the shared Pro-Gly-Pro extension — that alters enzymatic residence time in preclinical assay media. This review maps the structural chemistry of these modifications, summarises the divergent signalling evidence for the parent heptapeptides Semax (ACTH(4-7)PGP, CAS 80714-61-0) and Selank (TP-7, CAS 129954-34-3), and catalogues the query vocabulary that links commercial inventory tokens to peer-reviewed literature. All content is strictly for research reference; not for human or veterinary use.

Terminal-Capping Chemistry: Why N-Acetylation and C-Amidation Matter

Exopeptidases — aminopeptidases at the N-terminus and carboxypeptidases at the C-terminus — are the primary clearance route for linear peptides shorter than ~15 residues in plasma and brain homogenates [1]. Potaman et al. (1991) showed that the native ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) is cleaved within minutes by rat brain aminopeptidases, with N-terminal methionine as the initial recognition site [1]. Two chemical strategies address this vulnerability:

• N-Acetylation replaces the free α-amino group with an acetyl cap (CH₃CO–), eliminating the positive charge that aminopeptidases require for substrate docking. This modification is shared by both n acetyl semax amidate peptide and n-acetyl selank peptide.
• C-Amidation converts the terminal carboxylic acid (–COOH) to a primary amide (–CONH₂), removing the negative charge recognised by carboxypeptidase A/B. NA-Semax Amidate carries both modifications; NA-Selank carries only the N-acetyl cap, as the C-terminal proline of the Pro-Gly-Pro tail already confers moderate carboxypeptidase resistance.

The shared Pro-Gly-Pro (PGP) tripeptide extension at the C-terminus of both parent heptapeptides is itself a stability element: proline residues flanking the cleavage site sterically hinder prolyl endopeptidase access, extending the functional window available for pathway-level investigation [1][2].

Semax: ACTH(4-10) Lineage and the BDNF/TrkB Axis

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of the adrenocorticotropic hormone fragment ACTH(4-10), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Critically, the (4-10) fragment does not bind the MC2 receptor on adrenal cortical cells and therefore does not stimulate cortisol production — its activity is mediated primarily through melanocortin receptors MC4R and, to a lesser extent, MC3R in central nervous system tissue [2][3].

Dolotov et al. (2003) demonstrated that a single intranasal administration of Semax significantly upregulated BDNF mRNA in the rat hippocampus and basal forebrain, with peak expression observed at 90 minutes post-administration [3]. Agapova et al. (2008) confirmed that this BDNF induction follows a biphasic temporal profile — an early peak at 1.5 hours and a secondary elevation at 8 hours — suggesting both transcriptional activation and mRNA stabilisation mechanisms [4]. Downstream, BDNF binds the TrkB receptor, activating PI3K/Akt and MAPK/ERK cascades that are central to synaptic plasticity and long-term potentiation in preclinical models [3][5].

In addition to neurotrophic signalling, Semax modulates monoaminergic transmission. Eremin et al. (2005) reported that Semax potentiates the firing rate of dopaminergic neurons in the ventral tegmental area and sensitises D₁-receptor-mediated signalling, without direct receptor binding, suggesting an indirect, permissive mechanism through neurotrophin-receptor crosstalk [2].

Selank: Tuftsin Lineage and GABAergic Modulation

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) extends the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro stability tail. Tuftsin is a natural fragment of the Fc domain of immunoglobulin G heavy chain, released by splenic tuftsin-endocarboxypeptidase, and activates phagocytic cells via Fc-receptor and neuropilin-1 signalling [6][7].

What is selank peptide in terms of its anxiolytic mechanism? Vyunova et al. (2018) reviewed the molecular pharmacology and concluded that Selank allosterically modulates GABA-A receptor complexes — increasing the number of specific [³H]GABA binding sites on synaptic membranes without altering receptor affinity [8]. This profile is mechanistically distinct from benzodiazepines, which enhance GABA-gated chloride conductance through a separate allosteric site. Filatova et al. (2017) further showed that Selank alters the expression of 45 neurotransmission-related genes in rat frontal cortex within one hour, including GABA-A receptor subunit transcripts, though the peptide alone did not directly shift GABA-A subunit mRNA levels — it instead modified the cellular response to GABA itself [9].

What does selank peptide do in immune-modulation models? Transcriptomic profiling by Medvedeva et al. (2014) identified that Selank altered 34 of 84 inflammation-related genes, including upregulation of interferon-alpha pathway components and bidirectional modulation of IL-6 — a signature consistent with its tuftsin heritage rather than a classical anxiolytic profile [10].

Divergent Pathways: Evidence Table

Ischemia and Transcriptomic Models: Semax Preclinical Evidence

Sudarkina et al. (2021) used a transient middle-cerebral-artery occlusion (tMCAO) model in rats and demonstrated that Semax administration reduced the expression of pro-inflammatory markers at the protein level in subcortical structures, with downregulation of pJNK and upregulation of pCREB — restoring signalling homeostasis disrupted by ischaemia-reperfusion injury [5]. Dergunova et al. (2021) confirmed at the transcriptome level that Semax suppressed mRNA transcripts for IL-1α, IL-1β, IL-6, CCL3 and CXCL2 in ischaemic rat cortex, positioning the peptide as an immune-gene modulator rather than a simple receptor agonist [11]. Medvedeva et al. (2017) extended these findings to intact (non-ischaemic) cortical tissue, showing that Semax altered expression of immune-response genes even under basal conditions, suggesting constitutive regulatory capacity [12].

Catalogue Vocabulary Crosswalk

The following table maps uncovered search-catalogue strings to their canonical compound identities and RUO scope classification. Strings are indexed verbatim from the source keyword inventory.

Frequently Asked Questions

What is na semax and how does the N-acetyl modification alter enzymatic resistance?

NA-Semax (n acetyl semax amidate peptide) is a terminally capped derivative of the heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro). The N-terminal acetyl group shields the methionine residue from aminopeptidase cleavage, while the C-terminal amide replaces the carboxylic acid to resist carboxypeptidase degradation. Potaman et al. (1991) demonstrated that the unmodified ACTH(4-10) fragment is rapidly degraded by rat brain homogenates; the dual-cap design of NA-Semax extends functional stability in preclinical assay conditions [1].

What is selank peptide and what distinguishes NA-Selank from the parent sequence?

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic extension of the endogenous tetrapeptide tuftsin, a fragment of immunoglobulin G heavy chain. The Pro-Gly-Pro tail shared with Semax confers resistance to prolyl endopeptidases. NA-Selank (na-selank, na selank peptide) adds an N-terminal acetyl group to further shield the threonine residue from aminopeptidase recognition, extending the window for GABAergic and immunomodulatory study in preclinical models [6][8].

What is the difference between a semax selank blend and individual compounds?

A semax selank blend (semax/selank blend, selank/semax blend, semax and selank peptides) combines two heptapeptides that share a C-terminal Pro-Gly-Pro motif but activate divergent pathways: Semax primarily upregulates BDNF/TrkB via MC4R agonism, while Selank allosterically modulates GABA-A receptors and stabilises endogenous enkephalins. In research catalogues the blend is a co-formulated lyophilisate; individual compounds allow pathway-specific investigation. No vendor is assessed or endorsed in this review.

What does selank peptide do in preclinical immune-modulation models?

Preclinical transcriptomic profiling shows Selank alters expression of 34 of 84 inflammation-related genes in rat frontal cortex within one hour, including induction of interferon-alpha and modulation of IL-6 [10]. Kolik et al. (2019) further demonstrated that Selank attenuates ethanol-induced memory impairment in rats, implicating GABA-enkephalin crosstalk [6].

Why do catalogue listings show semax 10mg and similar fill-mass labels?

The label semax 10mg denotes a lyophilised fill mass per vial — the gross peptide content including counter-ion (typically trifluoroacetate or acetate salt). Actual net peptide content depends on salt form and purity, which should be verified against the lot-specific certificate of analysis. The related string semax/selank peptide similarly denotes a co-formulated research product, not a standardised pharmacopoeial preparation.

Where to Source for Research

Researchers procuring NA-Semax Amidate or NA-Selank for in-vitro or animal-model investigation should verify peptide identity by mass spectrometry and purity by RP-HPLC against the lot-specific certificate of analysis. Several reagent suppliers currently list these compounds for research use:

• Short Chain Aminos — primary catalogue source for lyophilised neuropeptide research reagents including Semax, Selank and their N-acetylated derivatives.
• BioPep — research-grade peptide supplier with COA-backed inventory.
• Catalyst Research — analytical-standard and bulk-lyophilisate peptide source.
• Apex Research Services — custom synthesis and catalogue neuropeptide reagents.

No vendor is assessed or endorsed in this review. Selection should be based on independent analytical verification.

Works Cited

1. Potaman VN et al. "N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat brain enzymes." Biochem Biophys Res Commun. 1991;176(2):741-746. PMID: 1851003.
2. Eremin KO et al. "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents." Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768.
3. Dolotov OV et al. "The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain." Dokl Biol Sci. 2003;391:292-295. PMID: 14556513.
4. Agapova TIu et al. "Effect of semax on the temporary dynamics of brain-derived neurotrophic factor mRNA expression in the rat hippocampus after global transient ischemia." Mol Biol (Mosk). 2008;42(5):768-773. PMID: 18756821.
5. Sudarkina OY et al. "Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion." Int J Mol Sci. 2021;22(12):6179. PMID: 34201112.
6. Kolik LG et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bull Exp Biol Med. 2019;167(5):641-644. PMID: 31625062.
7. Siebert A et al. "Tuftsin — Properties and Analogs." Curr Med Chem. 2017;24(35):3711-3727. PMID: 28745220.
8. Vyunova TV et al. "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741.
9. Filatova E et al. "GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells." Front Pharmacol. 2017;8:89. PMID: 28293190.
10. Medvedeva EV et al. "The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia." BMC Genomics. 2014;15:228. PMID: 24661604.
11. Dergunova LV et al. "The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain." Mol Biol (Mosk). 2021;55(3):402-411. PMID: 34097675.
12. Medvedeva EV et al. "Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats." Mol Genet Genomics. 2017;292(3):635-653. PMID: 28255762.

This article is strictly for research reference; not for human or veterinary use. No vendor is assessed or endorsed. Researchers should verify all compound identities against lot-specific certificates of analysis before use in any experimental protocol.